95.50
1.07 (1.13%)
| Previous Close | 94.43 |
| Open | 95.39 |
| Volume | 1,314,553 |
| Avg. Volume (3M) | 2,367,882 |
| Market Cap | 15,117,649,920 |
| Price / Earnings (TTM) | 11.95 |
| Price / Earnings (Forward) | 22.52 |
| Price / Sales | 3.67 |
| Price / Book | 6.95 |
| 52 Weeks Range | |
| Earnings Date | 31 Jul 2025 |
| Profit Margin | -22.27% |
| Operating Margin (TTM) | 17.67% |
| Diluted EPS (TTM) | -6.08 |
| Quarterly Revenue Growth (YOY) | -3.30% |
| Total Debt/Equity (MRQ) | 110.09% |
| Current Ratio (MRQ) | 1.86 |
| Operating Cash Flow (TTM) | 1.00 B |
| Levered Free Cash Flow (TTM) | 381.00 M |
| Return on Assets (TTM) | 4.96% |
| Return on Equity (TTM) | -23.85% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | Illumina, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -3.0 |
| Average | -1.50 |
|
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Core |
| % Held by Insiders | 0.19% |
| % Held by Institutions | 101.16% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Guardcap Asset Management Ltd | 31 Mar 2025 | 2,071,095 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 128.00 (Evercore ISI Group, 34.03%) | Buy |
| Median | 105.00 (9.95%) | |
| Low | 80.00 (Citigroup, -16.23%) | Sell |
| Average | 108.00 (13.09%) | |
| Total | 2 Buy, 4 Hold, 2 Sell | |
| Avg. Price @ Call | 98.53 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 04 Aug 2025 | 105.00 (9.95%) | Hold | 98.44 |
| Barclays | 01 Aug 2025 | 90.00 (-5.76%) | Sell | 94.66 |
| 24 Jun 2025 | 85.00 (-10.99%) | Sell | 91.52 | |
| Canaccord Genuity | 01 Aug 2025 | 105.00 (9.95%) | Hold | 94.66 |
| 11 Jun 2025 | 99.00 (3.66%) | Hold | 87.54 | |
| RBC Capital | 01 Aug 2025 | 126.00 (31.94%) | Buy | 94.66 |
| Baird | 28 Jul 2025 | 105.00 (9.95%) | Hold | 109.88 |
| Scotiabank | 11 Jul 2025 | 125.00 (30.89%) | Hold | 99.25 |
| Citigroup | 09 Jul 2025 | 80.00 (-16.23%) | Sell | 97.44 |
| Evercore ISI Group | 08 Jul 2025 | 128.00 (34.03%) | Buy | 99.27 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 31 Jul 2025 | Announcement | Illumina Reports Financial Results for Second Quarter of Fiscal Year 2025 |
| 30 Jul 2025 | Announcement | Illumina enhances flagship assay to accelerate access to comprehensive tumor profiling |
| 10 Jul 2025 | Announcement | Illumina named to TIME's World's Most Sustainable Companies list for the second consecutive year |
| 10 Jul 2025 | Announcement | Illumina to Announce Second Quarter 2025 Financial Results on Thursday, July 31, 2025 |
| 23 Jun 2025 | Announcement | Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy |
| 23 Jun 2025 | Announcement | Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina |
| 10 Jun 2025 | Announcement | lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |